ARS Pharmaceuticals Inc. (SPRY)
SPRY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/0001193125-26-097478-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SPRY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001671858 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $84.3M |
| Net income | -$171.3M |
| Operating income | -$179.4M |
| Net margin | -203.3% |
| Operating margin | -212.9% |
| Revenue growth | -5.5% |
| Cash | $41.3M |
| Total assets | $327.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $25.6M cash; operating cash flow -$45.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 100,528,400 (2026-11-03); 98,848,611 a year earlier; 95,997,252 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $37.7M | -$35.6M | -$33.7M | $25.6M | $121.8M | $122.1M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $33.7M | -$62.3M | -$60.9M | $8.2M | $96.7M | $116.9M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $22.7M | -$60.6M | -$44.9M | $24.3M | $96.5M | $99.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $28.1M | -$41.3M | -$43.5M | $41.3M | $96.4M | $84.3M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $32.5M | -$51.2M | -$47.0M | $59.6M | $96.2M | $142.8M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $15.7M | -$44.9M | -$39.6M | $51.5M | No debt tags | $112.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $8.0M | -$33.9M | -$40.7M | $39.9M | No debt tags | $97.1M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $86.6M | $49.9M | $42.0M | $50.8M | $0 | $89.1M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-01-31 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 550 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +39.4% |
| 1 month | -4.0% |
| 3 months | -36.2% |
| Year to date | -66.6% |
| 1 year | -53.7% |
| From 52-week high | -70.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
| RZLT | Rezolute Inc. Common Stock (NV) | $3.58 | -2.05% | $346.3M |
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| AVIR | Atea Pharmaceuticals Inc. | $4.12 | -4.19% | $330.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier